Japan· JP-4291073F1029
タゼメトスタット臭化水素酸塩
A tazemetostat product containing タゼメトスタット臭化水素酸塩, registered in Japan by エーザイ, on the national reimbursement list. The same ATC class is registered in 2 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Tazemetostat is registered in 2 of 19 countries.
Countries holding a registration under ATC L01XX72 (tazemetostat), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 1 of them publish a price we can compare per daily dose
Tazemetostat · ATC L01XX72
2 / 19 countries
- Japan
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- タゼメトスタット臭化水素酸塩
- Manufacturer
- エーザイ
- Country
- Japan (JP)
- ATC code
- L01XX72
- ATC class
- Tazemetostat
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
219 interactions on record for tazemetostat.
Graded by severity as the source publishes them — 47 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tazemetostat · interactions on record
219 records
- 47 severe
- 167 moderate
- 5 minor
Most severe, free to view
- AprepitantA04AD12severe
- PrasugrelB01AC22severe
- VorapaxarB01AC26severe
- RivaroxabanB01AF01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01XX72
Tazemetostat, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/837cfdf3-ec85-421a-8b66-ae7dd67a28a8 GET /v1/drugs/837cfdf3-ec85-421a-8b66-ae7dd67a28a8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２００ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291073F1029",
"category": "内用薬",
"price_yen": 3004,
"generic_name": "タゼメトスタット臭化水素酸塩",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about tazemetostat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.